Last reviewed · How we verify
lactoferrin and oral iron
Lactoferrin and oral iron, marketed by Cairo University, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of clear primary indication and revenue data, which may limit strategic planning and market positioning.
At a glance
| Generic name | lactoferrin and oral iron |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy (NA)
- Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates. (NA)
- Lactoferrin Use in ICU Patients (PHASE4)
- Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related Quality of Life in Older Patients (NA)
- Efficacy and Safety of Lactoferrin in Heart Failure Patients (PHASE4)
- Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction (NA)
- Lactoferrin With Ferrous Gluconate Versus Ferrous Gluconate in Treatment of Iron Deficiency Anemia During Pregnancy (PHASE4)
- Effect of Lactoferrin Supplementation on Urinary Tract Infections in Infants. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lactoferrin and oral iron CI brief — competitive landscape report
- lactoferrin and oral iron updates RSS · CI watch RSS
- Cairo University portfolio CI